Tony K L Kiang1, Nilufar Partovi2,3, R Jean Shapiro4, Jacob M Berman3, Abby C Collier3, Mary H H Ensom3. 1. Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group Centre for Pharmacy and Health Research, University of Alberta, Room 3-142D, 11361-87 Ave, Edmonton, AB, T6G 2E1, Canada. tkiang@ualberta.ca. 2. Department of Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada. 3. Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. 4. Department of Nephrology, Vancouver General Hospital, Vancouver, BC, Canada.
Abstract
BACKGROUND AND OBJECTIVES: The hematological side effects associated with mycophenolic acid (MPA) are relatively common and have severe consequences. The majority of literature data have not shown clear consistency in the MPA exposure-neutropenia relationship. We hypothesized that (i) adult de novo kidney transplant recipients who develop neutropenia have relatively higher dose-normalized MPA exposure than patients without neutropenia, and (ii) the observed neutropenia may be explained by polymorphisms in metabolism and/or transporter genes responsible for MPA disposition. METHODS: Adult kidney transplant recipients on steady-state tacrolimus and MPA, not receiving a corticosteroid, and with stable renal function were recruited for investigation at three periods post-transplant (1, 3, and 12 months; n = 21, 17, and 13, respectively). Clinical variables (age, weight, MPA daily dose, albumin, serum creatinine, absolute neutrophil count), tacrolimus and MPA concentrations (for exposure calculation), and genotypes (UGT2B7 G211T, UGT2B7 C802T, UGT1A9 T-275A, UGT1A9 T98C, MRP2 C-24T, MRP2 G1249A, OATP1B1 A388G, OATP1B1 C463A) were characterized. RESULTS: A significant inverse association between dose-normalized MPA exposure (a surrogate marker for apparent MPA clearance) and absolute neutrophil count in all three study periods (r2 ~ 0.3-0.7) was observed. No associations between characterized single nucleotide polymorphisms and MPA exposure or absolute neutrophil count were established. However, significant alterations in the minor allele frequencies of UGT2B7*2 C802T, UGT1A9 T275A, and MRP2 G1249A were evident. CONCLUSION: These findings support the clinical strategy for conducting MPA therapeutic drug monitoring in adult kidney transplant patients on steroid-free immunosuppressant therapy. The novel population genomic analysis data warrant further epidemiological investigations in a larger study sample.
BACKGROUND AND OBJECTIVES: The hematological side effects associated with mycophenolic acid (MPA) are relatively common and have severe consequences. The majority of literature data have not shown clear consistency in the MPA exposure-neutropenia relationship. We hypothesized that (i) adult de novo kidney transplant recipients who develop neutropenia have relatively higher dose-normalized MPA exposure than patients without neutropenia, and (ii) the observed neutropenia may be explained by polymorphisms in metabolism and/or transporter genes responsible for MPA disposition. METHODS: Adult kidney transplant recipients on steady-state tacrolimus and MPA, not receiving a corticosteroid, and with stable renal function were recruited for investigation at three periods post-transplant (1, 3, and 12 months; n = 21, 17, and 13, respectively). Clinical variables (age, weight, MPA daily dose, albumin, serum creatinine, absolute neutrophil count), tacrolimus and MPA concentrations (for exposure calculation), and genotypes (UGT2B7G211T, UGT2B7C802T, UGT1A9T-275A, UGT1A9T98C, MRP2C-24T, MRP2G1249A, OATP1B1A388G, OATP1B1 C463A) were characterized. RESULTS: A significant inverse association between dose-normalized MPA exposure (a surrogate marker for apparent MPA clearance) and absolute neutrophil count in all three study periods (r2 ~ 0.3-0.7) was observed. No associations between characterized single nucleotide polymorphisms and MPA exposure or absolute neutrophil count were established. However, significant alterations in the minor allele frequencies of UGT2B7*2 C802T, UGT1A9T275A, and MRP2G1249A were evident. CONCLUSION: These findings support the clinical strategy for conducting MPA therapeutic drug monitoring in adult kidney transplant patients on steroid-free immunosuppressant therapy. The novel population genomic analysis data warrant further epidemiological investigations in a larger study sample.
Authors: Jorge Andrade-Sierra; Enrique Rojas-Campos; Ernesto Cardona-Muñoz; Luis A Evangelista-Carrillo; Abel Puentes-Camacho; Orlando Lugo-López; Benjamín Gómez; Carlos Valdespino; Ignacio Cerrillos; Miguel Medina-Pérez; Basilio Jalomo; Juan J Nieves; Mario Sandoval; Francisco Ramos-Solano; Francisco Monteón-Ramos; Alfonso M Cueto-Manzano Journal: Nefrologia Date: 2014 Impact factor: 2.033
Authors: Jean-Baptiste Woillard; Nicolas Picard; Antoine Thierry; Guy Touchard; Pierre Marquet Journal: Pharmacogenet Genomics Date: 2014-05 Impact factor: 2.089
Authors: Vineetha Koroth Edavana; Rosalind B Penney; Aiwei Yao-Borengasser; Athena Starlard-Davenport; Ishwori B Dhakal; Susan Kadlubar Journal: Int J Cancer Res Mol Mech Date: 2015-09-22
Authors: M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq Journal: Clin Chem Date: 2001-01 Impact factor: 8.327
Authors: David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino Journal: Transplantation Date: 2019-10 Impact factor: 4.939